As COVID-19 both worldwide and in the United States, two separate efforts of a medical solution, move to find the virus spreading. At the University of Nebraska, the first patients have volunteered for an experimental drug COVID-19 test treatment. And in Washington Kaiser Permanente Health Research Institute, researchers recruit people started testing a possible vaccine. A number of US passengers were taken aboard the cruise ship Diamond Princess in Nebraska quarantine; two of these passengers have agreed in a study to remdesivir, originally developed an antiviral drug to Ebola, but caused that showed encouraging results in animals in the fight against SARS and MERS, two other diseases participate from Corona. The drug is designed to treat infections that are moderate to severe, and is aimed at the most intense symptoms. To qualify remdesivir study by the National Institute of race Allergy and Infectious Diseases (NIAID), the patients were positive for COVID-19 and have pneumonia. diagnosed by the cruise ship of more than two dozen people with COVID-19, which have been brought to quarantine in Nebraska, four required hospitalization and two developed pneumonia. These two patients were asked if they wanted to volunteer for the study, and both agree, says Dr. Andre Kalil, a professor of medicine in the Division of Infectious Diseases at the University of Nebraska Medical Center. Finally, the study includes 400 patients; The first results will not be analyzed due to complete by the first 100 treatment. Given the relatively low rate of grade moderate to severe patients affected in the United States, at this point, says Kalil that NIAID plans to work with health officials from other countries with higher volumes of cases, including Korea, Japan and Italy. For the moment, the process will remain open for three years to the number required to recruit patients. It is updated here with our daily newsletter crown. This study tells Kalil was also designed to be more flexible than most drug studies. “This is not just an attempt to remdesivir,” he says. “It will look at how [COVID-19] possible therapies and remdesivir is only the first. Let’s say that a couple of months from now we realize that remdesivir is a good drug, it works better than placebo …. Then the patients who received placebo, the drug would be available, and we will move towards a test different medication. If remdesivir is not effective, then we would get removed from the study and another drug to be tested against placebo. it is a dynamic, fast way to run a randomized trial. “the design is a way to test antiviral drugs against accelerating COVID-19 because infections are ongoing, and there is still no treatment. Meanwhile, other labs are working on developing vaccines that would provide some protection against the virus in the first place. The vaccine trial, along most (and which is also guarded by NIAID) is currently recruiting the first participant of Kaiser Permanente Health Research Institute in Washington. Unlike remdesivir study, this study will enroll healthy volunteers. Dr. Lisa Jackson, the principal investigator of the study, says that 45 healthy people are being recruited to test three different doses of the vaccine. Kaiser is currently thousands of requests for information online every day received from persons interested in participating. Phone researchers evaluated contact with volunteers their suitability for the study. Once participants are selected, they are one of three doses of vaccine being tested are given. Scientists will monitor the patients immune responses after this injection and then every patient a second type of injection (same dose). The goal is to find out what dose is most effective, and whether you need one or two shots of this dose. They will look for levels of antibodies that the immune system of the body produces against the so-called spike protein, a protein that the virus surface of the SARS-CoV-2-19 responsible for COVID Stud born. Scientists analyze levels of antibodies in the participants a year after their second vaccination, so the results are not at least 12 are available up to 18 months, says NIAID Director Dr. Anthony Fauci. Since the crown as it could be with a vaccine against this particular virus in the production of future vaccines crown as well as useful behind COVID-19 appear to be more common to see, anyway. Please send any suggestions, cables and [email protected] stories.